Medicare Part D coverage · metoclopramide · RxCUI 2380570

metoclopramide 15 MG/ACTUAT Nasal Spray [Gimoti]

Per the CMS 2026 Part D formulary file, metoclopramide 15 MG/ACTUAT Nasal Spray [Gimoti] is covered by 1 Medicare Part D plans (0% of enrollable products), averaging Tier 2, with prior authorization required on 100% of covering formularies.

0%
Plan coverage
1
Plans covering
T2
Avg tier
100%
Prior auth required

Verify with CMS →

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.

What the CMS Formulary Data Shows for metoclopramide 15 MG/ACTUAT Nasal Spray [Gimoti]

Per the CMS 2026 Part D formulary file, metoclopramide 15 MG/ACTUAT Nasal Spray [Gimoti] (RxNorm concept RXCUI 2380570, generic name metoclopramide) appears on 1 distinct formulary file spanning 1 Medicare Part D plan offering - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 2 to Tier 2, with a cross-plan average of Tier 2.

Real-world access to metoclopramide 15 MG/ACTUAT Nasal Spray [Gimoti] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 402,098 Part D beneficiaries filled metoclopramide 15 MG/ACTUAT Nasal Spray [Gimoti] in 2023, with total plan-and-beneficiary spending of $10,436,006 and an average per-beneficiary annual cost of $25.95. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry metoclopramide 15 MG/ACTUAT Nasal Spray [Gimoti] today.

Coverage Details

Formularies covering
1
Plans covering
1
Coverage rate
0%
Tier range
Tier 2, Generic
Average tier
Tier 2, Generic

Restrictions

Prior authorization required
100% of formularies
Step therapy required
0% of formularies
Quantity limits
100% of formularies

2023 Medicare Spending

Beneficiaries
402,098
Total spending
$10,436,006
Avg per beneficiary
$25.95

Tier Distribution Across Plans

1 plans
Tier 2, Generic

Medicare Advantage Plans (MA-PD) Covering metoclopramide 15 MG/ACTUAT Nasal Spray [Gimoti]

1 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
CalOptima Health OneCare Complete (HMO D-SNP) Orange County Health Authority T2 Yes $0 CA

Frequently Asked Questions

Is metoclopramide 15 MG/ACTUAT Nasal Spray [Gimoti] covered by Medicare Part D?

Yes, metoclopramide 15 MG/ACTUAT Nasal Spray [Gimoti] is covered by 1 Medicare Part D plans (0% of all Part D formularies).

What tier is metoclopramide 15 MG/ACTUAT Nasal Spray [Gimoti] on Medicare Part D plans?

metoclopramide 15 MG/ACTUAT Nasal Spray [Gimoti] averages Tier 2 across Part D plans, ranging from Tier 2 to Tier 2.

Does metoclopramide 15 MG/ACTUAT Nasal Spray [Gimoti] require prior authorization?

100% of Part D formularies require prior authorization for metoclopramide 15 MG/ACTUAT Nasal Spray [Gimoti]. Step therapy: 0%. Quantity limits: 100%.

How much does Medicare spend on metoclopramide 15 MG/ACTUAT Nasal Spray [Gimoti]?

In 2023, total Medicare Part D spending on metoclopramide 15 MG/ACTUAT Nasal Spray [Gimoti] was $10,436,006, covering 402,098 beneficiaries. The average spend per beneficiary was $25.95.

Read our methodology - how this data is sourced, computed, and verified.

Nationwide similar Part D drugs

Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.

Closest average formulary tier

Similar prior-authorization rate

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare